目的探讨吉西他滨与顺铂联用治疗晚期非小细胞肺癌临床效果及安全性。方法选取我院2008年7月至2011年5月收治晚期非小细胞肺癌患者60例,采用随机数字表法分为对照组与吉西他滨组,均采用顺铂(30mg/m2,d1-3)治疗,其中对照组30例,加用多西他赛(50mg/m2,d1、d8)治疗;吉西他滨组30例,加用多西他赛(1000mg/m2,d1、d8)治疗;疗程均为3周;比较两组患者临床症状缓解情况,骨髓抑制以及消化道反应等不良反应发生情况等。结果对照组与吉西他滨组完全缓解例数分别为3例、5例;部分缓解例数分别为11例,10例;临床治疗总有效率分别为46.7%、50.0%;两组患者临床治疗总有效率组间比较差异无统计学意义(P>0.05);吉西他滨组患者白细胞、血小板及血红蛋白等骨髓抑制不良反应发生情况明显优于对照组,组间比较差异有统计学意义(P<0.05);两组患者恶心呕吐、便秘及腹泻等消化道不良反应发生情况组间比较差异无统计学意义(P<0.05);两组患者局部静脉炎发生情况组间比较差异无统计学意义(P<0.05);且吉西他滨组患者乏力、脱发等不良反应发生情况明显优于对照组,组间比较差异有统计学意义(P<0.05)。结论吉西他滨与顺铂联用治疗晚期非小细胞肺癌能够有效缓解临床症状,减少骨髓抑制、乏力及脱发等不良反应发生。 Objective To investigate the clinical efficacy and safety of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer. Methods Sixty patients with advanced non-small cell lung cancer who were admitted to our hospital from July 2008 to May 2011 were randomly divided into control group and gemcitabine group. All patients were treated with cisplatin (30mg / m2, d1-3) , 30 cases in the control group were treated with docetaxel (50mg / m2, d1, d8), 30 cases in gemcitabine group were treated with docetaxel (1000mg / m2, d1, d8) Weeks; compare the two groups of patients with clinical symptoms, bone marrow suppression and gastrointestinal reactions and other adverse reactions occur. Results The complete remission cases in control group and gemcitabine group were 3 cases and 5 cases respectively. The partial relief cases were 11 cases and 10 cases respectively. The total effective rates of clinical treatment were 46.7% and 50.0% respectively. The total clinical treatment of both groups was There was no significant difference between the efficacy groups (P> 0.05). The incidence of bone marrow suppression adverse reactions such as leucocyte, platelet and hemoglobin in gemcitabine group was significantly better than that in the control group (P <0.05). Nausea and vomiting in both groups, constipation and diarrhea and other gastrointestinal adverse reactions were no significant difference between groups (P <0.05); two groups of patients with local phlebitis incidence was no significant difference between groups (P <0.05 ). The occurrence of adverse reactions such as fatigue and alopecia in gemcitabine group was significantly better than that in control group, with significant difference between the two groups (P <0.05). Conclusion Combination of gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer can effectively relieve clinical symptoms and reduce the occurrence of adverse reactions such as myelosuppression, fatigue and hair loss.